Prognostic association of demographic and clinical factors with the change rates of symptoms and depression among patients with hepatocellular carcinoma
To identify the predictive value of demographic and clinical factors for determining changes in physical and depressive symptom among hepatocellular carcinoma (HCC) patients over time.
We performed a prospective cohort study of 128 patients newly diagnosed with HCC in Taiwan. Each patient had four time-point data after the follow-up. Patients’ physical symptoms were evaluated with the Edmonton Symptom Assessment System (ESAS). Psychological symptoms were evaluated with the Hospital Anxiety and Depression Scale (HADS). Clinical factors and demographic characteristics were predictors of physical and psychological symptoms, as estimated by a generalized estimating equation (GEE).
We found that patients who had a smoking habit and Barcelona Clinic Liver Cancer (BCLC) Stage B disease underwent radiofrequency ablation therapy (RFA) or liver resection, and those who had higher alanine aminotransferase (GPT) level reported more symptoms from baseline to 1 month. Symptoms increased from baseline to 3 months in elderly patients and patients with higher GPT levels. Additionally, patients who had jobs, underwent liver resection, and had BCLC Stage C disease had increased symptoms of depression from baseline to 1 month; in particular, BCLC Stage D disease had negative long-term effects on depression scores from baseline to four-time points following therapy.
Advanced BCLC stage and undergoing RFA or liver resection were most closely associated with worsening physical and psychological symptoms over time. Clinical professionals should pay attention to these factors that affect physical and psychological symptoms during treatment.
KeywordsHepatocellular carcinoma (HCC) Symptom management theory (SMT) Symptom Depression
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C (2013) Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clinical gastroenterology and hepatology: the official clinical practice. J Am Gastroenterol Assoc 11(11):1413–1421.e1411. https://doi.org/10.1016/j.cgh.2013.04.039 Google Scholar
- 3.Wu Q, Qin SK (2013) Features and treatment options of Chinese hepatocellular carcinoma. Chin Clin Oncol 2(4):38. https://doi.org/10.3978/j.issn.2304-3865.2013.09.07 Google Scholar
- 5.Yoon SK, Chun HG (2013) Status of hepatocellular carcinoma in South Korea. Chin Clin Oncol 2(4):39. https://doi.org/10.3978/j.issn.2304-3865.2013.11.08 Google Scholar
- 6.Ministry of Health and Welfare (2017) Cancer registry annual report. Ministry of Health and Welfare, Taiwan http://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=8084. Accessed 15 Aug 2018Google Scholar
- 7.Patrick DL, Ferketich SL, Frame PS, Harris JJ, Hendricks CB, Levin B, Link MP, Lustig C, McLaughlin J, Ried LD, Turrisi AT 3rd, Unutzer J, Vernon SW (2003) National Institutes of Health state-of-the-science conference statement: symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002. J Natl Cancer Inst 95(15):1110–1117CrossRefGoogle Scholar
- 10.Shun SC, Chen CH, Sheu JC, Liang JD, Yang JC, Lai YH (2012) Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study. Oncologist 17(5):732–739. https://doi.org/10.1634/theoncologist.2011-0368 CrossRefGoogle Scholar
- 12.Wible BC, Rilling WS, Drescher P, Hieb RA, Saeian K, Frangakis C, Chen Y, Eastwood D, Kim HS (2010) Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. J Vasc Interv Radiol 21(7):1024–1030. https://doi.org/10.1016/j.jvir.2010.03.005 CrossRefGoogle Scholar
- 15.Krebber AMH, Buffart LM, Kleijn G, Riepma IC, de Bree R, Leemans CR, Becker A, Brug J, van Straten A, Cuijpers P, Verdonck-de Leeuw IM (2014) Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psycho-oncology 23(2):121–130. https://doi.org/10.1002/pon.3409 CrossRefGoogle Scholar
- 19.Sullivan DR, Forsberg CW, Ganzini L, Au DH, Gould MK, Provenzale D, Slatore CG (2016) Longitudinal changes in depression symptoms and survival among patients with lung cancer: a national cohort assessment. J Clin Oncol 34(33):3984–3991. https://doi.org/10.1200/jco.2016.66.8459 CrossRefGoogle Scholar
- 21.Lydiatt WM, Moran J, Burke WJ (2009) A review of depression in the head and neck cancer patient. Clin Adv Hematol Oncol 7(6):397–403Google Scholar
- 25.Byam J, Renz J, Millis JM (2013) Liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr 2(1):22–30. https://doi.org/10.3978/j.issn.2304-3881.2012.11.03 Google Scholar
- 28.Haberman M (1999) The measurement of symptom distress. In: Yarbro CH, Frogge MH, Goodman M (eds) Cancer symptom management. Jones & Barlett, Boston, p 11Google Scholar
- 30.Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9Google Scholar
- 40.Nanashima A, Abo T, Nonaka T, Fukuoka H, Hidaka S, Takeshita H, Ichikawa T, Sawai T, Yasutake T, Nakao K, Nagayasu T (2011) Prognosis of patients with hepatocellular carcinoma after hepatic resection: are elderly patients suitable for surgery? J Surg Oncol 104(3):284–291. https://doi.org/10.1002/jso.21932 CrossRefGoogle Scholar